整合21基因复发评分与临床病理特征的工具(RSClin)在早期乳腺癌中的开发与验证
研究开发并验证了RSClin工具,该工具整合21基因复发评分(RS)与肿瘤分级、大小和年龄,用于个体化预后和预测化疗获益。
要点
- RSClin整合RS与肿瘤分级、大小、年龄,提供比单一因素更精准的预后信息。
- 外部验证中RSClin估计风险与观察10年风险高度一致(Lin concordance 0.962)。
- RSClin可个体化估计绝对化疗获益,指导淋巴结阴性早期乳腺癌辅助化疗决策。
核心结论
- RSClin工具整合临床病理与基因组风险,为淋巴结阴性早期乳腺癌辅助化疗提供比单独临床病理或基因组数据更个体化的信息。
研究设计与样本
- 基于患者特异性荟萃分析开发RSClin,纳入10,004例激素受体阳性、HER2阴性、淋巴结阴性早期乳腺癌女性,来自B-14(n=577)和TAILORx(n=4,854内分泌治疗;n=4,573化疗)试验。
- 使用似然比检验比较RSClin与单独RS或临床病理因素的Cox模型。
- 外部验证在Clalit注册研究的1,098例女性中比较RSClin估计风险与观察风险。
关键数值与推荐
- 在55岁、1.5cm中级别肿瘤女性中,RS从11到50时,RSClin估计的绝对化疗获益范围为0%至15%。
临床怎么用
- RSClin可结合RS与临床病理特征,更精准地个体化评估早期乳腺癌患者远处复发风险和化疗获益,辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 21-gene recurrence score (RS) is prognostic for distant recurrence (DR) and predictive for chemotherapy benefit in early breast cancer, whereas clinical-pathological factors are only prognostic. Integration of genomic and clinical features offers the potential to guide adjuvant chemotherapy use with greater precision. METHODS: We developed a new tool (RSClin) that integrates RS with tumor grade, tumor size, and age using a patient-specific meta-analysis including 10,004 women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 (n = 577) and TAILORx (n = 4,854) trials or plus chemotherapy in TAILORx (n = 4,573). Cox models for RSClin were compared with RS alone and clinical-pathological features alone using likelihood ratio tests. RSClin estimates of DR used a baseline risk with TAILORx event rates to reflect current medical practice. A patient-specific estimator of absolute chemotherapy benefit was computed using individualized relative chemotherapy effect from the randomized TAILORx and B-20 trials. External validation of risk estimation was performed by comparing RSClin estimated risk and observed risk in 1,098 women in the Clalit registry. RESULTS: RSClin provides more prognostic information (likelihood ratio χ2) for DR than RS or clinical-pathological factors alone (both P < .001, likelihood ratio test). In external validation, the RSClin risk estimate was prognostic for DR risk in the Clalit registry (P < .001) and the estimated risk closely approximated the observed 10-year risk (Lin concordance 0.962). The absolute chemotherapy benefit estimate ranges from 0% to 15% as the RS ranges from 11 to 50 using RSClin in a 55-year-old woman with a 1.5-cm intermediate-grade tumor. CONCLUSION: The RSClin tool integrates clinical-pathological and genomic risk to guide adjuvant chemotherapy in node-negative breast cancer and provides more individualized information than clinical-pathological or genomic data alone.
引用
- Sparano JA, Crager MR, Tang G, et al. Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. J Clin Oncol. 2020. PMID: 33306425. doi:10.1200/JCO.20.03007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。